Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US

被引：0
|
作者：
Epperla, Narendranath [1 ]
Lucero, Melanie [2 ]
Bailey, Tom [3 ]
Mirams, Laura [3 ]
Cheung, Jolenta [3 ]
Amet, Mona [3 ]
Milligan, Gary [3 ]
Keir, Chris [4 ]
Chen, Lei [5 ]
机构：
[1] Ohio State Univ, Columbus, OH USA
[2] ADC Therapeut Amer Inc, New Providence, NJ USA
[3] Adelphi Real World, Macclesfield, Cheshire, England
[4] ADC Therapeut, Murray Hill, NJ USA
[5] ADC Therapeut, New Providence, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
loncastuximab tesirine; CD19-targeted chimeric antigen receptor T-cell therapy; real-world evidence; treatment sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-370
引用
收藏
页码：S476 / S476
页数：1
相关论文
共 50 条
  • [1] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [2] Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine
    Hamadani, Mehdi
    Lucero, Melanie
    Devos, Jakob D.
    Chen, Lei
    EJHAEM, 2024, 5 (05): : 1110 - 1113
  • [3] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Xu, Bo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) : 707 - 719
  • [4] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Bo Xu
    European Journal of Clinical Pharmacology, 2022, 78 : 707 - 719
  • [5] Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma
    Goparaju, Krishna
    Caimi, Paolo F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) : 1373 - 1381
  • [6] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Epperla, Narendranath
    Lucero, Melanie
    Bailey, Tom
    Mirams, Laura
    Cheung, Jolenta
    Amet, Mona
    Milligan, Gary
    Chen, Lei
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [7] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
    Furqan, Fateeha
    Hamadani, Mehdi
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [8] Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US
    Chihara, Dai
    Liao, Laura
    Tkacz, Joseph
    Lewing, Benjamin
    Franco, Anjali
    Kilgore, Karl M.
    Nastoupil, Loretta J.
    Chen, Lei
    BLOOD, 2022, 140 : 2421 - 2423
  • [9] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA
    Anthony Markham
    Zaina T. Al-Salama
    Drugs & Therapy Perspectives, 2022, 38 : 261 - 267
  • [10] Real-World Experience Using Tafasitamab Plus Lenalidomide and/or Loncastuximab Tesirine in a Predominately Hispanic Population with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Latiolais, Heidi
    Horowitz, Justin
    Michalek, Joel
    Duque, Adolfo Enrique Diaz
    BLOOD, 2024, 144 : 7780 - 7781
12345